Business Wire

IDRx Announces Updated Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial of IDRX-42 in Advanced Gastrointestinal Stromal Tumors (GIST) at CTOS 2024

PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing precision therapeutics for the treatment of cancers with ...
Nasdaq

Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs

Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
Nasdaq

Kymera Therapeutics Reports Positive Phase 1 Results for KT-621, a Once-Daily Oral STAT6 Degrader, Surpassing Targets and Demonstrating Strong Safety Profile

Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. KT-621 demonstrated superior Th2 biomarker reductions compared to ...
Seeking Alpha

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...